Bimekizumab beneficial for psoriatic arthritis in phase 3 trials
Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.
Related Articles
Similar reduction in CV risk with different add-on RA treatments
Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with…
BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?
Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape…
Treatment goals in late-onset RA should match those for younger patients
People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same…
The metabolic syndrome may influence the risk for gout
The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.
Treatment goals in late-onset RA should match those for younger patients
People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same…
SURPASS: Secukinumab vs adalimumab biosimilar in axSpA
Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.
LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome
Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren’s syndrome in a phase 2 study.
Abortion restrictions impede methotrexate access for some rheumatology patients
Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the…
New score could predict ILD development in people with SSc
Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.
JUVE-BASIS: Support for baricitinib in juvenile arthritis
The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.